Case Studies

How sites really feel about using ePRO.

The AIR2 Trial, a pivotal Phase III study sponsored by Asthmatx, investigates the safety and effectiveness of Bronchial Thermoplasty™, the first non-drug treatment for asthma, using the Alair® System. 300 patients at 35 global sites use the LogPad to record and transmit daily symptomatic data on their experiences following treatment. Two principal investigators took to time to tell PHT about the benefits and challenges of using ePRO in a trial.

Can a call center and a LogPad reduce hospitalizationsand improve QoL?

Published: 2006

Temple's unique disease management study uses the LogPad to investigate the impact of a pulmonary call center on COPD patient hospitalizations, deaths, lung function and quality of life. The LogPad uses automatic graded scoring and real-time alerts at the site to identify warning signs of exacerbations, and notifies patients when they need to contact the call center based on these scores. Early results have reduced hospitalizations significantly - but don't take our word for it. To learn more, read the case study or watch the news report, which features patient and study coordinator interviews.

Author: Shelia Rocchio
Published: March 2010
Source: Applied Clinical Trials On-line

Sanofi Pasteur had used electronic patient reported outcome (ePRO) solutions provider PHT Corporation in previous trials. "eDiaries motivate subjects to complete their daily questionnaires. In addition, it is much more efficacious to ask subjects how they feel at a precise moment and get an immediate, accurate answer," said Vicki Tyler, Clinical Trial Manager at Sanofi Pasteur's Massachusetts facility, who oversees the Clostridium difficile study

Published: Oct 2, 2008
Source: Applied Clinical Trials Online

Patti Hall, RN, CCRC, director of clinical research at Family Allergy, explained, the immediate information they receive as a subject completes a questionnaire enables her team of nine coordinators and investigators to know in real time if a subject is being compliant and answering the questionnaire. "It gives us the opportunity to keep an eye on patient safety and also to make sure they complete every question and enter data correctly," she said. "The questionnaire is designed so the patient has to answer each question appropriately before proceeding to the next one."

Author: Valdo Arnera, MD
Published: October 2010
Source: Applied Clinical Trials Online
ALK is currently developing a house dust mite (HDM) immunotherapy tablet. In the latest HDM clinical trial, ALK used an ePRO system from PHT to enable subjects to record their experiences in the trial. ePRO is the electronic capture of patient reported outcomes (PRO) data from study subjects. This was the seventh trial in which ALK used ePRO solutions from PHT.